uploads///Chart

What Drove GlaxoSmithKline’s Consumer Healthcare Segment in Q2

By

Updated

Consumer Healthcare

GlaxoSmithKline’s (GSK) Consumer Healthcare segment includes its wellness, oral health, nutrition, and skin health products. In the second quarter, the segment’s revenue grew 3% YoY (year-over-year) at constant exchange rates to ~1.8 billion British pounds, as shown in the chart below. GlaxoSmithKline bought out Novartis’s (NVS) stake in the companies’ consumer healthcare joint venture on June 1.

Article continues below advertisement

Product performance in Q2 2018

  • Nutrition revenue fell 7% YoY to 154 million pounds, as a result of 1% operating revenue growth and a 9% impact by foreign exchange.
  • Oral health revenue grew 1% YoY to 611 million pounds, as a result of 5% operating revenue growth and a 4% impact by foreign exchange.
  • Skin health revenue grew 3% YoY to 162 million pounds, as a result of 8% operating revenue growth and a 5% impact by foreign exchange.
  • Wellness revenue fell 3% YoY to 901 million pounds, as a result of 1% operating revenue growth and a 4% impact by foreign exchange.

Performance by region in the second quarter

  • US revenue was flat YoY at ~428 million pounds, as a result of 4% operating revenue growth and a 4% impact by foreign exchange.
  • European revenue fell 1% YoY to ~573 million pounds, as a result of a 1% fall in operating revenue and a marginal impact by foreign exchange.
  • International revenue fell 2% YoY to ~827 million pounds, as a result of 5% operating revenue growth and a 7% impact by foreign exchange.

The Invesco BLDRS Europe Select ADR ETF (ADRU) invests 2.9% of its holdings in GlaxoSmithKline, 6.2% in Novartis, 2.9% in AstraZeneca (AZN), and 2.4% in Novo Nordisk (NVO).

Advertisement

More From Market Realist